Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

CONCLUSIONS: Compared to ADT alone, the early (within 120 days of beginning ADT) addition of taxane-based chemotherapy to ADT for hormone-sensitive prostate cancer probably prolongs both overall and disease-specific survival and delays disease progression. There may be an increase in toxicity with taxane-based chemotherapy in combination with ADT. There may also be a small, clinically unimportant improvement in quality of life at 12 months with taxane-based chemotherapy and ADT treatment.
PMID: 30320443 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - October 15, 2018 Category: General Medicine Authors: Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P Tags: Cochrane Database Syst Rev Source Type: research